/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ALVOTECH SA

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.68 0.0087(0.87%) ALVO at 04 Dec 2025 04:25 PM Drug Manufacturers - Specialty & Generic
Lowest Today 4.33
Highest Today 4.69
Today’s Open 4.49
Prev. Close 4.6
52 Week High 13.70
52 Week Low 4.32
Day’s Range: Low 4.33 High 4.69
52-Week Range: Low 4.32 High 13.70
1 day return -
1 Week return -9.0
1 month return -3.72
3 month return -42.16
6 month return -57.33
1 year return -59.84
3 year return -29.11
5 year return -53.5
10 year return -

Institutional Holdings

Vanguard Total Intl Stock Index Inv 0.50

Vanguard Emerging Mkts Stock Idx Inv 0.44

T. Rowe Price International Discovery 0.37

T. Rowe Price International Small-Cap Eq 0.34

Eaton Vance Emerg & Frntr Countrs Eq I 0.28

Vanguard Instl Ttl Intl Stk Mkt Idx TrII 0.26

iShares Biotechnology ETF 0.21

L&G Frontier Markets Eq Z USD Acc 0.18

Eaton Vance Glbl Macro Abs Ret Advtg I 0.16

T. Rowe Price Intl Small-Cap Eq Tr-C 0.08

Vanguard FTSE All-Wld ex-US ETF 0.07

Eaton Vance Strategic Income Class C 0.06

Fidelity Nasdaq Composite Index 0.05

iShares Nasdaq US Biotech ETF USD Acc 0.05

Schwab Emerging Markets Equity ETF™ 0.04

Vanguard Instl Ttl Intl Stck Mkt Idx Tr 0.04

Eaton Vance Glbl Macr Absolute Return I 0.04

Morgan Stanley Global Macro Abs. Return 0.03

Vanguard Total World Stock ETF 0.02

SSGA Emerging Markets Equity Index 0.02

Market Status

Strong Buy: 2

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1720.04 M

PB Ratio 0.0

PE Ratio 24.0

Enterprise Value 2747.46 M

Total Assets 1221.40 M

Volume 1233558

Company Financials

Annual Revenue FY23:61902000 61.9M, FY22:83029000 83.0M, FY21:36772000 36.8M, FY20:66616000 66.6M, FY19:31918000 31.9M

Annual Profit FY23:-71268000 -71.3M, FY22:18934000 18.9M, FY21:36772000 36.8M, FY20:66616000 66.6M, FY19:31918000 31.9M

Annual Net worth FY23:-595681000 -595.7M, FY22:-513580000 -513.6M, FY21:-101504000 -101.5M, FY20:-170044000 -170.0M, FY19:-209876000 -209.9M

Quarterly Revenue Q3/2025:113953000 114.0M, Q2/2025:173239000 173.2M, Q1/2025:132765000 132.8M, Q3/2024:102887000 102.9M, Q2/2024:198753000 198.8M

Quarterly Profit Q3/2025:78925000 78.9M, Q2/2025:99414000 99.4M, Q1/2025:67318000 67.3M, Q3/2024:63075000 63.1M, Q2/2024:153543000 153.5M

Quarterly Net worth Q3/2025:-5218000 -5.2M, Q2/2025:32038000 32.0M, Q1/2025:109680000 109.7M, Q3/2024:-11393000 -11.4M, Q2/2024:65224999 65.2M

Fund house & investment objective

Company Information Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Organisation Drug Manufacturers - Specialty & Generic

Employees 1012

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Vilhelm Robert Wessman

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow